Fukunaga, M
Current Research Status (2026): As of early 2026, there are no published human clinical trials specifically investigating the safety, efficacy, or pharmacokinetic interactions of combining MOTS-c and retatrutide
QW: Supervision, Writing review & editing, Investigation, Resources
Standard practice involves injecting air into the vial to equalise pressure before drawing liquid, but this introduces room-temperature air that accelerates oxidation of the peptide in solution
Clinical data shows that 70% of patients report side effects diminish significantly by week 6, though individual timelines vary
The drugs are also expensive: GLP-1 medications typically cost between $930 and $1,350 a month without insurance, and research shows the majority of people on them are paying at least part of that cost, if not all, themselves, particularly as some insurance plans are becoming stricter when it comes to what theyll pay for